The present study investigated safety/toxicity profile of fixed dose combination of Ofloxacin-Ornidazole injection in Mus musculus mice at three dose levels, ranging from asymptomatic to high dose. To enhance the antimicrobial spectrum of the quinolones against anaerobic organisms and gram positive bacteria, fixed dose combination of Ofloxacin and Ornidazole injection was introduced. It has been found highly effective as well as synergistic and has the potential of usage for empirical therapy because of extended spectrum. A 30 days repeat dose subchronic toxicity study was conducted on mice (male and female). Various physiological, hematological and biochemical parameters were studied. There were no signs of toxicity observed at any dose level used in this study. No mortality was seen in any of the treatment groups. Hematological as well as physiological parameters were unaltered at three dose levels in Ofloxacin-Ornidazole treatment groups. Results suggest that the fixed dose combination of Ofloxacin-Ornidazole injection is non toxic even at maximum dose level.
INTRODUCTION
The development of the fluoroquinolones has resulted in antimicrobial agents with enhanced gram-negative activity, including moderate activity against Pseudomonas aeruginosa [1, 2] . However, despite the broad antibacterial spectrum of quinolones, most anaerobic pathogens and several gram-positive strains such as Staphylococci and Streptococci are only moderately susceptible [2, 3] . Thus, in some clinical situations, a combination with other antibacterial agents is needed to broaden the antibacterial spectrum. Examples are miscellaneous infections with aerobic and anaerobic bacteria (such as aspiration pneumonia or intra-abdominal infections) for which initial therapy has to be empiric, or the empiric therapy of febrile neutropenic patients [4] . Ornidazole have an antibacterial spectrum that includes most anaerobes [4, 5] and single-dose ornidazole is an important alternative agent for the treatment of many conditions than other nitroimidazoles [4, 6] . Thus this combination was developed to cover all treatment related aspects and to widen the spectrum of activity of these two agents.
The other aspect of innovating fixed dose combinations (FDCs) is emergence of high resistance of Pseudomonas aeruginosa against various commonly used antibiotics, especially in fluoroquinolones, which is an alarming situation. The control of drug resistant Pseudomonas aeruginosa required rational prescribing and proper use of antibiotics [1, 7] .
Ofloxacin is a synthetic fluoroquinolone that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA *Address correspondence to this author at the Intellectual Scientific Division, Venus Medicine Research Centre, Venus Remedies limited, Hill Top, Industrial Estate, Jharmajiri EPIP, Phase I Extension, Baddi (H.P), 173205, India; Tel: +91-1795-302100; Fax: +91-1795-302023; E-mail: vmrc@venusremedies.com replication [6, 8] whereas Ornidazole is a nitroimidazole anti-infective medication that is mainly used in the treatment of infections caused by susceptible organisms, particularly anaerobic bacteria and protozoa [9] . The nitro group of Ornidazole is chemically reduced by ferredoxin (or a ferredoxin-linked metabolic process) and the products are responsible for disrupting the DNA helical structure, thus inhibiting nucleic acid synthesis. Anaerobic bacteria and sensitive protozoal organisms take Ornidazole selectively because of the ability of these organisms to reduce Ornidazole to its active form intracellularly [5] .
The parenteral formulation of ofloxacin has been developed with favorable pharmacokinetic properties [10] , including high serum concentrations and a long terminal half-life, resulting in a higher area under the concentration-time curve (AUC) than other fluroquinolones [11, 12] . Ornidazole is already a parentral formulation. Apart from this there are no available reports of kinetic interaction reported between Ofloxacin and Ornidazole [5, 13] .
The major hurdle in fabricating fixed dose combination is their toxicity profile which may also worsened in a synergistic pattern. Several reports are available on toxicity study of individual agents [14] but safety profile of combination product has not been established yet. We have first time conducted the toxicity study on FDC Ofloxacin-Ornidazole. The purpose of current study was to evaluate safety profile/ toxicity potential of fixed dose combination OfloxacinOrnidazole injection in mice by sub chronic dosing.
MATERIAL AND METHOD

Animals
Healthy Mus musculus mice (male and female mice, 15-25 g weight) were divided into four groups (three treatment groups and one control group). Each group consists of 6 male and 6 female animals. Animals were provided with standard diet (pellets) supplied by Amrut feed India and water was given ad libitum. They were housed in polyurethane cages (six in each) at controlled room temperature of 29 ±2°C and a relative humidity of 50.5%, and a constant lightdark schedule (12 hours light and 12 hour dark cycle).
Experimental Design and Drug Treatment
Ofloxacin-Ornidazole was given as intravenous injection at three dose levels i.e. 56 mg/kg, 175 mg/kg and 560 mg/kg correspond to low dose, intermediate dose and high dose respectively (1 : 2.5 ratio of Ofloxacin : Ornidazole) for thirty days. Normal saline was administered to the animals of control group as sham treatment. Treatment was done once daily for continuous 30 days.
Physical parameters (body weights, food and water intake) and local injury were studied throughout the treatment. Mortality if any, in all the groups, during the course of treatment was also recorded. Autopsy was done if animal died during course of treatment. At the end of treatment haematological, biochemical (liver function tests & renal function tests) and histological parameters were studied. The organs were quickly blotted, weighed on digital balance and processed for histological studies. The organ body weight ratio of each organ was calculated and tissues were processed for H& E staining.
Hematological
Blood was collected by cardiac puncture. Blood samples were analyzed for routine hematological parameters. Blood cell count was done with blood smears. Hemogram was performed on ACT diff-2 Hematolgy Analyzer (Beckman Coulter India Ltd., Mumbai, India).
Biochemical Parameters
Biochemical parameters were performed in serum sample. Gluatmic oxaloacetic transaminase (GOT), gluatmic pyruvic transaminase activities (GPT), alkaline phosphatase (ALP) activities and triglycerides (TG), bilirubin, cholesterol, blood urea nitrogen (BUN), protein, creatinine and glucose levels were estimated. Sodium, potassium and chloride levels were estimated for evaluating electrolyte balance in serum. All parameters were studied by Merck semi auto analyzer by using Merck analytical kits.
Histological Examination
At the end of treatment animals were sacrificed and various organs like liver, kidney, lungs and gonads were collected for histological examinations. All the organs were immediately fixed in 10% buffered formalin. H&E staining was done and slides were studied for histological changes.
Statistical Analysis
Results are shown as Mean ± SD. Significance of difference between groups was evaluated by using ANOVA. If ANOVA shows significant differences, post hoc analysis was performed with Tukey test. P<0.05 was considered as statistically significant.
The study protocol for study was approved by Institutional animal ethics committee of Institute for Toxicological Studies, Pune, India. Drug was procured from Venus Remedies Limited.
RESULTS
Physical Parameters
No physical changes were observed throughout the dosing period. There was no significant change in the mean body weight of the animals in FDC treated groups as compared to vehicle treated control group at the end of treatment.
Hematology
No significant changes were observed in red blood cell (RBC), ESR, hemoglobin (Hb), total leukocyte counts (TLC) and platelet counts in all the treated groups as compared to respective control groups (Tables 1 and 2) . PCV decreased in high dose treated groups which was insignificant ( Tables 1  and 2 ).
Biochemical Parameters
In male and female mice groups, no significant changes were seen in serum creatinine, bilirubin, total protein, sodium, potassium and plasma chloride levels in all the groups as compared to control group (Tables 3 and 4) . Slight increase was observed at high dose level in serum glucose, BUN, GPT, GOT activities, alkaline phosphatase activities in all the treated groups as compared to respective control group, however change was statistically insignificant (Tables 3 and 4).
Histological Examination
There were no significant treatment related histopathological changes observed in organs of all the treated groups as compared to control.
DISCUSSION
This study demonstrates the safety profile of potential FDC Ofloxacin-Ornidazole in mice. Despite the broad antibacterial spectrum of Ofloxacin, most anaerobic and several gram-positive bacteria are only moderately susceptible. To cover this lacuna in spectrum of activity, a combination with onidazole was hypothesized. A primary effect of quinolones is inhibition of bacterial DNA synthesis in the presence of competent RNA and protein synthesis [3, 15] . Thus, interactions and antagonism with other potent protein synthesis inhibitors cannot be ruled out.
Combinations of quinolones with other antimicrobial agents investigated in in-vitro and in vivo studies rarely showed antagonistic effects [16] . Against anaerobic bacteria the results of combination drug were very encouraging. Combination of quinolones with ornidazole, and other drugs investigated, showed synergistic activity with Ofloxacin [13, 17] . The available reports showed synergy for the combinations of ciprofloxacin with metronidazole (a similar combination) against members of the family Enterobacteriaceae, peptostreptococci, and clostridia [18] . Other studies have also reported similar synergism with quinolones and nitro-imidazoles [13] . The major issue which required to be addressed was evaluation of toxicity profile of FDC.
Our study was designed to investigate possible toxic outcomes of this promising therapeutic choice. There was no signs of local injury and inflammatory response at site of injection in the treated groups. No physical changes were observed during the study period of 30 days in all the treatment groups. Increase in body weights and growth of treated animals of either sex were of similar pattern as in control groups. Published evidences also suggested no treatmentrelated changes in physical and organs in any species [19, 20] .
Blood was evaluated for hematological toxicity of FDC. Hemogram was estimated and results had shown no deleterious effect on blood cell count, haemoglobin and other related parameters in treated animals (Table 1 and 2) . There was no significant changes in plasma alkaline phosphatase, GOT and GPT activities in Ofloxacin-Ornidazole treated groups of either sex as compared to the respective control group (Table  3 and 4) . This confirms the safety profile of Ofloxacin/ Ornidazole injection in hepatic related aspects. Available reports proved efficacy of Ofloxacin as well as 5-nitroimidazoles (Ornidazole) against a range of microorganisms and also found it safe in the short-term as well as the longterm usage [21] [22] [23] .
Ofloxacin-ornidazole eliminated through renal excretion, thus it is mandatory to estimate effects of FDC on kidney functions [5, 6, 24] . Biochemical parameters related to kidney function were evaluated and no significant differences were observed in BUN, creatinine, glucose and proteins with respect to control (Table 3 and 4) . Previous reports also suggested no dose-limiting toxicity observed in the trial of ornidazole and ofloxacin. It was found safe, well tolerated, and associated with improvement in the inflammatory symptoms [20, 23, 24 ].
There were no signs of toxicity were seen in any of organ in histopathological analysis. No mortality was occurred throughout the study. Thus histopathological studies provides supports to the safety data of other physiological, biochemical and heamatological parameters of OfloxacinOrnidazole injection [8, 21] .
In summary, our data suggest that combination of Ofloxacin-Ornidazole is safe even at higher doses than intended to be use for human treatment as it indicates no clinically relevant alterations of any of physiological and biochemical parameters. A beneficial effect of combination against grampositive and anaerobic pathogens could be demonstrated/established with bacterial susceptibility tests .
It can be concluded that in preclinical settings (subchronic dosing), a parenteral therapy consisting of modern quinolones together with imidazole derivative ornidazole as fixed dose combination appears to be active and offers no obvious toxicity at any dose level. 
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